Effects of a medication assistance program with medication therapy management on the health of renal transplant recipients

Marie A. Chisholm, Christina A. Spivey, Laura L Mulloy

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose. The effects of a medication assistance program with medication therapy management (MTM) on the clinical outcomes and health-related quality of life (HQOL) of renal transplant recipients were studied. Methods. All renal transplant recipients who were enrolled in the Medication Access Program at the Medical College of Georgia for at least one year were included in the study. Patients' demographics, number of graft rejections (for one year preenrollment and one year postenrollment), and diagnoses of hypertension, diabetes, and dyslipidemia were recorded and confirmed by medical and pharmacy records. The use of antihypertensive, antidiabetic, antilipemic, and immunosuppressant agents and laboratory values for fasting blood glucose, glycosylated hemoglobin (HbA1c), blood pressure, low-density-lipoprotein (LDL) cholesterol, total cholesterol, triglycerides, and serum immunosuppressant concentrations were identified for one year preenrollment and one year postenrollment. HQOL was measured at the time of enrollment and one year postenrollment. Results. Thirty-six adult renal transplant recipients were included in the study. All patients had hypertension, 72% had dyslipidemia, and 42% had diabetes. Patients received significantly more antihypertensive agents postenrollment versus preenrollment (p < 0.001) and significantly more antidiabetic agents (p = 0.004) and antilipemics (p = 0.001). Measures of fasting blood glucose, glycosylated hemoglobin, LDL cholesterol, total cholesterol, triglycerides, blood pressure, and number of graft rejections decreased from preenrollment levels (p < 0.01). A significantly greater number of patients reached target serum cyclosporine levels postenrollment versus preenrollment (p = 0.008). HQOL was significantly increased one year postenrollment (p < 0.01). Conclusion. A medication assistance program that included MTM services improved medication access, clinical outcomes, and HQOL in renal transplant recipients.

Original languageEnglish (US)
Pages (from-to)1506-1512
Number of pages7
JournalAmerican Journal of Health-System Pharmacy
Volume64
Issue number14
DOIs
StatePublished - Jul 15 2007

Fingerprint

Medication Therapy Management
Quality of Life
Kidney
Hypolipidemic Agents
Health
Glycosylated Hemoglobin A
Graft Rejection
Immunosuppressive Agents
Dyslipidemias
Hypoglycemic Agents
LDL Cholesterol
Antihypertensive Agents
Blood Glucose
Fasting
Triglycerides
Cholesterol
Blood Pressure
Hypertension
Serum
Cyclosporine

Keywords

  • Antidiabetic agents
  • Antilipemic agents
  • Blood levels
  • Charity
  • Clinical pharmacy
  • Cyclosporine
  • Diabetes mellitus
  • Drug distribution
  • Drug use
  • Graft rejection
  • Hyperlipidemia
  • Hypertension
  • Hypotensive agents
  • Immunosuppressive agents
  • Outcomes

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy

Cite this

Effects of a medication assistance program with medication therapy management on the health of renal transplant recipients. / Chisholm, Marie A.; Spivey, Christina A.; Mulloy, Laura L.

In: American Journal of Health-System Pharmacy, Vol. 64, No. 14, 15.07.2007, p. 1506-1512.

Research output: Contribution to journalArticle

@article{766c0a23367b430e8e8b36f0256b34bd,
title = "Effects of a medication assistance program with medication therapy management on the health of renal transplant recipients",
abstract = "Purpose. The effects of a medication assistance program with medication therapy management (MTM) on the clinical outcomes and health-related quality of life (HQOL) of renal transplant recipients were studied. Methods. All renal transplant recipients who were enrolled in the Medication Access Program at the Medical College of Georgia for at least one year were included in the study. Patients' demographics, number of graft rejections (for one year preenrollment and one year postenrollment), and diagnoses of hypertension, diabetes, and dyslipidemia were recorded and confirmed by medical and pharmacy records. The use of antihypertensive, antidiabetic, antilipemic, and immunosuppressant agents and laboratory values for fasting blood glucose, glycosylated hemoglobin (HbA1c), blood pressure, low-density-lipoprotein (LDL) cholesterol, total cholesterol, triglycerides, and serum immunosuppressant concentrations were identified for one year preenrollment and one year postenrollment. HQOL was measured at the time of enrollment and one year postenrollment. Results. Thirty-six adult renal transplant recipients were included in the study. All patients had hypertension, 72{\%} had dyslipidemia, and 42{\%} had diabetes. Patients received significantly more antihypertensive agents postenrollment versus preenrollment (p < 0.001) and significantly more antidiabetic agents (p = 0.004) and antilipemics (p = 0.001). Measures of fasting blood glucose, glycosylated hemoglobin, LDL cholesterol, total cholesterol, triglycerides, blood pressure, and number of graft rejections decreased from preenrollment levels (p < 0.01). A significantly greater number of patients reached target serum cyclosporine levels postenrollment versus preenrollment (p = 0.008). HQOL was significantly increased one year postenrollment (p < 0.01). Conclusion. A medication assistance program that included MTM services improved medication access, clinical outcomes, and HQOL in renal transplant recipients.",
keywords = "Antidiabetic agents, Antilipemic agents, Blood levels, Charity, Clinical pharmacy, Cyclosporine, Diabetes mellitus, Drug distribution, Drug use, Graft rejection, Hyperlipidemia, Hypertension, Hypotensive agents, Immunosuppressive agents, Outcomes",
author = "Chisholm, {Marie A.} and Spivey, {Christina A.} and Mulloy, {Laura L}",
year = "2007",
month = "7",
day = "15",
doi = "10.2146/ajhp060634",
language = "English (US)",
volume = "64",
pages = "1506--1512",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "14",

}

TY - JOUR

T1 - Effects of a medication assistance program with medication therapy management on the health of renal transplant recipients

AU - Chisholm, Marie A.

AU - Spivey, Christina A.

AU - Mulloy, Laura L

PY - 2007/7/15

Y1 - 2007/7/15

N2 - Purpose. The effects of a medication assistance program with medication therapy management (MTM) on the clinical outcomes and health-related quality of life (HQOL) of renal transplant recipients were studied. Methods. All renal transplant recipients who were enrolled in the Medication Access Program at the Medical College of Georgia for at least one year were included in the study. Patients' demographics, number of graft rejections (for one year preenrollment and one year postenrollment), and diagnoses of hypertension, diabetes, and dyslipidemia were recorded and confirmed by medical and pharmacy records. The use of antihypertensive, antidiabetic, antilipemic, and immunosuppressant agents and laboratory values for fasting blood glucose, glycosylated hemoglobin (HbA1c), blood pressure, low-density-lipoprotein (LDL) cholesterol, total cholesterol, triglycerides, and serum immunosuppressant concentrations were identified for one year preenrollment and one year postenrollment. HQOL was measured at the time of enrollment and one year postenrollment. Results. Thirty-six adult renal transplant recipients were included in the study. All patients had hypertension, 72% had dyslipidemia, and 42% had diabetes. Patients received significantly more antihypertensive agents postenrollment versus preenrollment (p < 0.001) and significantly more antidiabetic agents (p = 0.004) and antilipemics (p = 0.001). Measures of fasting blood glucose, glycosylated hemoglobin, LDL cholesterol, total cholesterol, triglycerides, blood pressure, and number of graft rejections decreased from preenrollment levels (p < 0.01). A significantly greater number of patients reached target serum cyclosporine levels postenrollment versus preenrollment (p = 0.008). HQOL was significantly increased one year postenrollment (p < 0.01). Conclusion. A medication assistance program that included MTM services improved medication access, clinical outcomes, and HQOL in renal transplant recipients.

AB - Purpose. The effects of a medication assistance program with medication therapy management (MTM) on the clinical outcomes and health-related quality of life (HQOL) of renal transplant recipients were studied. Methods. All renal transplant recipients who were enrolled in the Medication Access Program at the Medical College of Georgia for at least one year were included in the study. Patients' demographics, number of graft rejections (for one year preenrollment and one year postenrollment), and diagnoses of hypertension, diabetes, and dyslipidemia were recorded and confirmed by medical and pharmacy records. The use of antihypertensive, antidiabetic, antilipemic, and immunosuppressant agents and laboratory values for fasting blood glucose, glycosylated hemoglobin (HbA1c), blood pressure, low-density-lipoprotein (LDL) cholesterol, total cholesterol, triglycerides, and serum immunosuppressant concentrations were identified for one year preenrollment and one year postenrollment. HQOL was measured at the time of enrollment and one year postenrollment. Results. Thirty-six adult renal transplant recipients were included in the study. All patients had hypertension, 72% had dyslipidemia, and 42% had diabetes. Patients received significantly more antihypertensive agents postenrollment versus preenrollment (p < 0.001) and significantly more antidiabetic agents (p = 0.004) and antilipemics (p = 0.001). Measures of fasting blood glucose, glycosylated hemoglobin, LDL cholesterol, total cholesterol, triglycerides, blood pressure, and number of graft rejections decreased from preenrollment levels (p < 0.01). A significantly greater number of patients reached target serum cyclosporine levels postenrollment versus preenrollment (p = 0.008). HQOL was significantly increased one year postenrollment (p < 0.01). Conclusion. A medication assistance program that included MTM services improved medication access, clinical outcomes, and HQOL in renal transplant recipients.

KW - Antidiabetic agents

KW - Antilipemic agents

KW - Blood levels

KW - Charity

KW - Clinical pharmacy

KW - Cyclosporine

KW - Diabetes mellitus

KW - Drug distribution

KW - Drug use

KW - Graft rejection

KW - Hyperlipidemia

KW - Hypertension

KW - Hypotensive agents

KW - Immunosuppressive agents

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=34447553667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447553667&partnerID=8YFLogxK

U2 - 10.2146/ajhp060634

DO - 10.2146/ajhp060634

M3 - Article

VL - 64

SP - 1506

EP - 1512

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 14

ER -